WideCells Group PLC Result of General Meeting (8984S)

TIDMWDC

RNS Number : 8984S

WideCells Group PLC

28 June 2018

28 June 2018

WideCells Group PLC ('WideCells Group' or 'the Group')

Result of General Meeting

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to announce that following the Group's General Meeting held earlier today, all resolutions were duly passed. As a result, the Placing (see announcements dated 10 May 2018, 5 June 2018, 11 June 2018 and 12 June 2018 for further information) is now unconditional, save for Admission.

An application has been made for admission of a total of 68,698,355 new ordinary shares of GBP0.0025 (Ordinary Shares) each, (being 67,865,022 Placing Shares and 833,333 Fee Shares, as set out in the Company's prospectus dated 12 June 2018) on the Official List of the FCA and to trading on the London Stock Exchange's main market for listed securities (Admission). Admission is expected to take place at 8.00 am on 29 June 2018.

Following Admission, the Company's total issued share capital will consist of 133,519,365 Ordinary Shares. As each ordinary share carries one vote the total number of voting rights attached to the ordinary shares in the Company is 133,519,365.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in ordinary shares in the Company in accordance with the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ----------------------------------------------------------------------------------------------------------------- 
 a)   Names                                      Peter Presland 
                                                  João Andrade 
                                                  Lopes Gil 
                                                  Peter Hollands 
                                                  David Bridgland 
                                                  Marilyn Orcharton 
                                                  Malcolm Glaister 
                                                  David Henriques 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 2    Reason for the notification 
       Increases in interests in ordinary shares 
---  ----------------------------------------------------------------------------------------------------------------- 
 a)   Position/status                            Directors of the Company 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 b)   Initial notification /Amendment            Initial notification 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ----------------------------------------------------------------------------------------------------------------- 
 a)   Name                                       WideCells Group PLC 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 b)   LEI                                        n/a 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ----------------------------------------------------------------------------------------------------------------- 
 a)   Description of the financial instrument,   Ordinary shares of GBP0.0025 each 
       type of instrument 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 b)   Identification code                        GB00BD060S65 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 c)   Nature of the transaction                  Placing 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 d)   Price(s) and volume(s)                     Name                  Price(s)   Volume(s) 
                                                  -------------------  ---------  ----------- 
                                                  Peter Presland 
                                                   João            3p         1,666,667 
                                                   Andrade               3p         333,333 
                                                   Lopes Gil             3p         266,667 
                                                   Peter Hollands        3p         166,667 
                                                   David Bridgland       3p         1,666,667 
                                                   Marilyn Orcharton     3p         166,667 
                                                   Malcolm Glaister      3p         500,000 
                                                   David Henriques       3p         1,333,333 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 d)   Aggregated information                      6,100,001 
       - Aggregated volume                        GBP183,000 (6,100,001 new ordinary shares at 3 pence per new 
       - Price                                    ordinary share) 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 e)   Date of the transaction                    29 June 2018 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 f)   Place of the transaction                   London Stock Exchange main market 
---  -----------------------------------------  ---------------------------------------------------------------------- 
 

**ENDS**

For further information, please visit the Group's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

 
 WideCells Group      CEO - João Andrade    Tel: +351 919 
  PLC                                             033 171 
-------------------  -------------------------  -------------- 
 Smaller Company      Broker - Jeremy Woodgate   Tel: +44 (0) 
  Capital Limited      & Rupert Williams          20 3651 2912 
-------------------  -------------------------  -------------- 
 Shard Capital        Broker - Damon Heath       Tel: +44 (0) 
  Partners LLP         & Erik Woolgar             20 7186 9950 
-------------------  -------------------------  -------------- 
 St Brides Partners   PR - Charlotte Page        Tel: +44 (0) 
  Limited              & Isabel de Salis          20 7236 1177 
-------------------  -------------------------  -------------- 
 

Notes to Editors

WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. This is achieved through three divisions:

The Group has three divisions:

-- CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.

-- WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to provide stem cell storage services and focus on stem cell research and regenerative medicine. Its international cryogenics division specialises in stem cell storage, with the Group currently offering umbilical cord blood and tissue storage services to clients in the UK and Europe under the brand name BabyCells.

-- Wideacademy: an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

-- Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of cord blood.

-- Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.

   --     82 illnesses can currently be treated using stem cell procedures. 

-- Despite initial storage often costing no more than a few GBPthousand, actual treatment can cost in the GBPhundreds of thousands

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR). On publication of this announcement, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ROMLIFLARDITFIT

(END) Dow Jones Newswires

June 28, 2018 05:30 ET (09:30 GMT)